Angiotensin Receptor Antagonists
"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
| Descriptor ID |
D057911
|
| MeSH Number(s) |
D27.505.519.162
|
| Concept/Terms |
Angiotensin Receptor Antagonists- Angiotensin Receptor Antagonists
- Antagonists, Angiotensin Receptor
- Receptor Antagonists, Angiotensin
- Angiotensin Receptor Blockers
- Receptor Blockers, Angiotensin
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".
This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 4 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 9 | 3 | 12 |
| 2021 | 1 | 4 | 5 |
| 2022 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.
-
Risk of Acute Kidney Injury Among Older Adults With Heart Failure and With Reduced Ejection Fraction Treated With Angiotensin-Neprilysin Inhibitor vs Renin-Angiotensin System Inhibitor in Routine Clinical Care. J Card Fail. 2023 Feb; 29(2):138-146.
-
Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity. Am J Med. 2022 12; 135(12):1468-1477.
-
Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25?000 Medicare beneficiaries. Eur J Heart Fail. 2022 Sep; 24(9):1506-1515.
-
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. Am Heart J. 2022 May; 247:76-89.
-
Laboratory monitoring to reduce adverse drug-related events: a mixed methods study. J Manag Care Spec Pharm. 2022 Jan; 28(1):16-25.
-
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021 12 01; 6(12):1415-1423.
-
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Pharmacotherapy. 2021 12; 41(12):998-1008.
-
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
-
Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
-
Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study. Am J Hypertens. 2021 04 20; 34(4):339-347.